Facilitators and barriers for clinical implementation of a 30-minute point-of-care test for
Neisseria gonorrhoeae and Chlamydia trachomatis into clinical care: a qualitative study
within sexual health services in England

Pacho A.,¹ Harding-Esch E.M.,^{1 2} Heming De-Allie E.G.,¹ Phillips L.¹, Furegato M.¹, Sadiq
S.T.,¹ *Fuller S.S.¹

*Corresponding author

¹ St George's University of London
Institute for Infection and Immunity
Applied Diagnostic Research and Evaluation Unit
Cranmer Terrace
London SW17 0RE

² Public Health England
HIV and STI Department
National Infection Service
61 Colindale Avenue
London NW9 5EQ

Abstract

Point-of-care tests (POCTs) to diagnose sexually transmitted infections (STIs) have potential to positively impact patient management and patient perceptions of clinical services. Yet there remains a disconnect between development of new technologies and their implementation into clinical care. With the advent of new STI POCTs arriving to the global market, guidance for their successful adoption and implementation into clinical services is urgently needed.

We conducted qualitative in-depth interviews with professionals prior to and post-implementation of a *Chlamydia trachomatis/Neisseria gonorrhoeae* POCT into clinical services in England to define key stakeholder roles and explore the process of POCT integration. Participants self-identified themselves as key stakeholders in the STI POCT adoption and/or implementation processes. Data consisted of interview transcripts, which were analysed thematically using NVIVO 11.

Six sexual health services were included in the study; three of which have implemented POCTs. We conducted 40 total interviews: 31 prior to POCT implementation and 9 follow-up post-implementation. Post-implementation data showed that implementation plans required little or no change during service evaluation. Lead clinicians and managers self-identified as key stakeholders for the decision to purchase, while nurses self-identified as “change champions” for implementation. Many identified senior clinical staff as those most likely to introduce and drive change. However, participants stressed the importance of engaging all clinical staff in implementation. While the accuracy of the POCT, its positive impact on patient management and the ease of its integration within existing pathways were

considered essential, costs of purchasing and utilising the technology were identified as central to the decision to purchase.

Our study shows that key decision-makers for adoption and implementation require STI POCTs to have laboratory-comparable accuracy and be affordable for purchase and ongoing use. Further, successful integration of POCTs into sexual health services relies on supportive interpersonal relationships between all levels of staff.

Background

Point-of-care tests (POCTs) to enable to rapid and appropriate management of sexually transmitted infections (STIs) have potential to positively impact infection control, disease progression, and patient perceptions of clinical services [1-3]. Despite the potential advantages STI POCTs may bring, these do not necessarily lead to their adoption into clinical services. Many POCTs have struggled to be purchased, implemented and integrated (“adopted”) into healthcare [4,5]. Guidance for adoption of new diagnostics into clinical care are usually premised on evidence-based medicine (EBM), which is predicated on robust clinical research determining best clinical practice [6,7]. Within England, the National Institute for Clinical Excellence (NICE) provides clinical practice guidance based on EBM [6,8]. However, many have argued there are significant deficits to relying on EBM alone to direct clinical practice [9]. Social and contextual forces influencing new diagnostics’ adoption are poorly understood and receive relatively little formal attention compared to clinical efficacy data [10,11]. Clinical practitioners have argued that their own clinical expertise - based on years of direct practice experience - is increasingly discounted in favour

of EBM's reliance on evidence from randomised controlled trials [9]. It has been suggested that key decision-makers consider social, structural and contextual factors as well as clinical trial data in their decision to implement new technologies [6,12].

Enquiries into facilitators and barriers to POCT adoption are particularly timely for sexual health: new rapid and POCTs for *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) are becoming increasingly available for clinical adoption [13]. The dual CT/NG nucleic acid amplification test (NAAT) provided by binx health is one such POCT; qualitative diagnosis of CT/NG is provided on the *io*® system within 30-minutes of sample input [13]. This POCT is currently CE-marked for use in Europe, and has received Food and Drug Administration (FDA) clearance in the USA for CT/NG detection in genital samples (female vaginal swabs and male urine; data currently under review by FDA for CLIA waiver) [13]. The *Facilitators to Adoption* study (2017-19) was developed to explore key social, structural and contextual facilitators and barriers in the process of adoption of the binx health *io* CT/NG Assay (the "binx POCT") into sexual health services in England.

Methods

We conducted a qualitative study of healthcare professionals (HCPs), commissioners and managers in English sexual health services, between April 2018 and October 2019. This study was conducted concurrently with an experimental model that sought to de-risk the adoption of the binx POCT by supplying instruments and CT/NG cartridges free-of-charge to clinical services, and assisting with data analysis to enable service evaluation of the binx POCT (with the ultimate goal of clinical adoption). The experimental model is reported elsewhere [14].

Invitation to the qualitative study was based on services' participation in the experimental model. Invitation to participate in the experimental model was advertised through the British Association for Sexual Health and HIV newsletter, to our previous collaborators and by word-of-mouth. Initially, 14 services expressed interest; six of these withdrew following telephone calls between the service leads and the research team to discuss the premise and mechanisms of the project. Services that withdrew felt the binx POCT would not be a good fit for their service, or could not supply (human) resources to take part in the experimental model. Two additional services withdrew following participation in a workshop where the study team and self-identified key stakeholders from the services discussed the practicalities of the project, and implementation and adoption. The two services that withdrew cited: belief that the binx POCT would increase cost / not be cost-efficient for their service, and lack of space to house even a single binx POCT instrument. Six services took part in the pre-implementation interviews, but three of these ultimately declined participation in the experimental model. Reasons for withdrawal included administrative and planning difficulties, and stakeholders reporting they felt there was a poor fit between the POCT and local clinical population. The latter resulted from the device not being approved for extragenital sampling, which was seen as a key requirement for clinics with high numbers of male patients reporting sex with men. The service recruitment process is shown in Fig 1.

Fig 1. Service recruitment and participation in qualitative interviews

For confidentiality purposes, participating services are not named in this report. Of the six services participating in the pre-implementation interviews, two are located in inner London, one is located in a mid-sized city in north England and three are peri-urban services located in south-east England. Service footfall in those clinics ranges considerably, with the smallest

service seeing ~500 patients per month to larger services seeing ~4000 patients a month. Of the three services that participated in the experimental model, Service 1 is a high-throughput service seeing an average of 2250 patients a month, located in inner London; Service 2 is a high throughput service located in south-east England seeing a combined average of 3550 patients a month; and Service 3 is a lower throughput service located in south-east England and sees a combined average of 500 patients a month, with testing conducted in general practice surgeries as well as the main sexual health clinic.

Qualitative, in-depth interviews were conducted with professionals identified via the experimental model who self-identified as key in either the decision-making process for adoption of new technologies, and/or implementing new technologies, into their current service. Informed consent was obtained from all respondents; those interviewed face to face provided written consent; verbal consent was recorded prior to interviews conducted over the phone. An initial set of interviews was conducted prior to the binx POCT implementation to explore: key decision-makers; structural and social facilitators/barriers to adoption of new technologies (specifically: diagnostics, information technology) into sexual health services; their opinions of the usefulness of POCTs for CT/NG, and POCTs for multiple STI infections, to their current service (Topic Guide1; supplement 1). Follow-up interviews were planned to take place post-implementation of the binx POCT to explore any changes in rationale or plans described in initial interviews (Topic Guide2; supplement 2). In pre-and post-implementation interviews, respondents were asked to describe service evaluation (prospective or actual) implementation processes in their own words and to identify facilitators and barriers to POCT adoption.

149 This study (reference 224413) received approval from the National Health Service (NHS)
150 Health Research Authority; it did not require further NHS Research Ethics Committee
151 review.

152

153 Interviews were conducted by AP, and analysis conducted by AP and SSF; both have >10
154 years' experience with qualitative research. Interviews were conducted one-on-one, either
155 face-to-face or via telephone depending on participants' preference, audio recorded and
156 transcribed verbatim. Transcripts for both sets of interviews were then checked for accuracy
157 against the audio recording by the interviewer and imported into NVivo 11 for analysis.

158

159 Transcripts were analysed using a thematic approach, where common themes are identified
160 across the dataset [15]. AP led the initial analysis and selected initial codes. SSF then
161 reviewed a random selection of transcripts, generated and assigned codes independently. All
162 codes were agreed on by SSF and AP prior to finalising analysis. A second analysis was
163 conducted following post-implementation interviews to check dataset comparability, which
164 was assessed independently by AP and SSF and agreed upon. Additional codes were added to
165 the post-implementation interviews analysis to identify and explain new concepts within the
166 data.

167

168 Comparison of implementation plans discussed in interviews conducted pre- and post-
169 implementation did not show significant differences. Therefore, we present our analysis here
170 as a whole, grouped under sub-headings to differentiate considerations respondents had for
171 post-study purchase versus those that focused primarily on product implementation. A full
172 list of nodes is shown in Fig 2 and Fig 3. We report our findings following the Completed
173 Standards for Reporting Qualitative Research (SRQR) (S1 SRQR checklist).

Fig 2. NVivo nodes ‘Prior to implementation’ interviews. Asterisks represent nodes that emerged independently of the questions asked by the interviewer (e.g. inductive nodes).

Fig 3. NVivo nodes ‘After implementation’ interview. Asterisks represent nodes that emerged independently of the questions asked by the interviewer (e.g. inductive nodes).

Results

Invitation to participate was sent to professionals identified via the experimental model who self-identified as key in either the decision-making process for adoption of new technologies and/or implementing new technologies, into their current service. Forty-eight invitations were sent to HCPs (including general practitioners who offered STI testing), commissioners and clinic managers; 31 (64.6%) participants took part in initial interviews. HCPs (clinicians, nurses, health advisors and healthcare assistants) comprised the majority of respondents (71%) (Table 1).

Clinic	Number of respondents	HCPs (%)	Lab (%)	Management (%)	Commissioners (%)
Clinic 1	6	4 (66.7%)	0 (0%)	2 (33.3%)	0 (0%)
Clinic 2	5	4 (80%)	0 (0%)	1 (20%)	0 (0%)
Clinic 3	5	2 (40%)	1 (20%)	1 (20%)	1 (20%)
Clinic 4	6	5 (83.3%)	1 (16.7%)	0 (0%)	0 (0%)
Clinic 5	4	3 (75%)	0 (0%)	1 (25%)	0 (0%)
Clinic 6	5	4 (80%)	0 (0%)	1 (20%)	0 (0%)

Total	31 (100%)	22 (71%)	2 (6.5%)	6 (19.3%)	1 (3.2%)
--------------	------------------	-----------------	-----------------	------------------	-----------------

Table 1: ‘Prior to implementation’ interviews

Professionals in clinical services that ultimately declined participation in the experimental model (3/6; 50%) were not eligible to participate in post-implementation interviews. Invitations to participate were sent to the 15 previous participants in the remaining three clinical services; nine of these (60%) participated. Of the nine respondents, the majority (7/9; 78%) were HCPs (Table 2).

Clinic	Number of respondents	HCPs (%)	Management (%)
Clinic 2	2	2 (100%)	0 (0%)
Clinic 3	2	1 (50%)	1 (50%)
Clinic 6	5	4 (80%)	1 (20%)
Total	9 (100%)	7 (78%)	2 (22%)

Table 2: ‘After implementation’ interviews

The interviewer, (AP), presented herself to respondents as an independent University researcher with no formal ties to the POCT company, in order to illicit both positive and negative comments about the tests. AP had prior experience of conducting research in sexual health, and as such, had a history of professional collaboration with some of the participants. Any familiarity with the participants had no impact on the questions asked during the interviews. There was no significant difference with respect to depth of responses, or reported feelings about use of the POCTs, between data collected from respondents who had prior history with AP, and those that did not.

208

209 **The case for purchase: perceived POCT costs and benefits**

210 As sensitivity and specificity of the binx POCT was expected to be comparable with existing
211 lab-based technologies, the costs of purchasing and utilising the new tests were identified as
212 central to the decision to purchase. Whenever financial cost was discussed, it was stressed by
213 respondents that POCTs would have to be proven to either be cost saving or cost neutral to
214 meet the benchmark of a successful business case for purchase. Respondents referred to
215 insufficient funding as the main reason why services do not adopt new technologies. This
216 health advisor told us:

217

218 ‘And I find that a bit unfortunate. That it’s all about cost. We can say that it’s about patient
219 choice and about patient experience, and everything. But the most important thing in this
220 current state of the [health service] is that it costs less. And that’s a bit frustrating sometimes,
221 really.’ – Health Advisor1, (C6)

222

223 Similarly, one clinician told us that even if new technology had potential to improve service
224 provision, cost may still act as ‘red tape’ in the purchase process:

225

226 ‘The biggest barrier to anything is the finances. If you're trying to introduce something that
227 may be a better way of doing it, but if it costs more, then it's very, very hard to introduce that.

228 So, I think that would be the main barrier.’ – Clinician1, (C4)

229

230 Although restricted funding was discussed by most respondents as a barrier, some felt that the
231 current economic climate may encourage innovation:

232

‘It’s a mix ... the current difficult or stressing financial climate gives an opportunity for things to be reviewed also so that you don’t look at doing the same thing. You’re under pressure to ask yourself, is there is a better way? Is there a more cost-effective way?’

– Clinician1, (C5)

Other respondents also discussed the value POCTs may add to the service that were beyond comparisons of incoming and outgoing costs. Keeping the service “modern,” as well as cost-effective, was seen by some respondents as providing the potential to avoid funding cuts to the service in the future.

‘Well, I think you have to keep the service modern. ... I won't be someone who puts everything in right up front without the evidence. But I do like to be an early adopter rather than dragged to the gate as it were. – Clinician1, (C2)

Drivers of POCT implementation

Clinical leads with positive attitudes towards new technologies were seen to foster the potential to bring innovation into their services. Respondents stressed that adoption of new technology required commitment from HCPs in leading roles in the service. These individuals were recognised as most likely to introduce new ideas and drive change:

‘I think these ideas generally come from the frontline. So I would say whoever the staff member is who’s come up with the idea is obviously key. I think the clinical lead, the [lead nurse] and the service manager, they’re like a trio that cover all areas of the service. They’re the ones that in the first instance should be deciding if [a new technology] is something we want to progress.’ – General Manager1, (C6)

‘I’d say the climate at the moment within the department is quite exciting and people are willing to try new things. And there’s an eagerness and an enthusiasm within the senior doctor team to start to move things forward definitely. And as I say our lead nurse is very proactive in new technologies and bringing us, wanting to lead us forward.’

– Nurse/Health Advisor1, (C4)

In interviews prior to implementation, most suggested that implementing changes to healthcare provision was enabled by supportive relationships and interactions between all members of staff. Respondents felt that it was crucial that junior staff be included in the process and given an opportunity to voice their opinions of changes:

‘I think when it comes to [service] evaluation, everyone is involved. It might not be all coming together at once, but it might be various teams getting feedback from various people. ... when it comes to evaluation, everyone's input is valid.’ – Nurse1, (C2)

POCT suitability

The design of the binx POCT was discussed by respondents as an important feature for consideration of how it would be used. For example, respondents discussed that a turn-around-time of 30 minutes would not enable the binx POCT to be used with all patients in a busy clinical setting. Respondents from one of the three services participating in clinical implementation raised this as an issue of concern, and a consultant from another service planned to re-design pathways so patients were occupied with other tasks (e.g. blood tests) while waiting for POCT results, to shorten the time patients felt they were waiting. Another idea to mitigate longer wait for results involved introduction of a sample-first pathway with POCT

patients, whereby patients would provide sample at triage and be brought into the consultation room only when their POCT results were ready. Several respondents felt that this test would only be suitable for selected patient groups (e.g. symptomatic patients, or sexual contacts of those found positive for infection). Yet this was not seen negatively: respondents explained that use of the POCT would bring significant value to their service. In particular, one clinician discussed that the desire for a one-size-fits-all test for STIs should not predicate use of less-than-ideal technologies:

‘You end up surrounded by people who want to get the perfect, you know, the perfect scenario before you launch into a new project... And then what happens is, nothing happens ... So, the perfect is the enemy of the good. ... you just have to make good. And set it up, run it, evaluate it.’ – Clinician1, (C6)

Respondents interviewed prior to implementation stressed the importance of published accuracy of the binx POCT compared to existing laboratory tests; the decision to bring the binx POCT into the clinic was predicated on comparable sensitivity and specificity. This topic was raised again in post-implementation interviews, with some suggesting it would take time to build trust in the accuracy of the binx POCT:

‘Do we trust the brand-new machine that we’ve got or do we trust the one that we’ve been using for a long time?’ – Healthcare Assistant1, (C1)

This same HCP went on to explain her nuanced understanding of accuracy and what that means in the current context of laboratory results:

‘So that’s tricky, but the way that I rationalised it in the end was that you’re going to get false positives either way. When we send off our swabs anyway now we can’t fully trust that they’re going to be correct.’ – Healthcare Assistant1, (C1)

However, the ability of the binx POCT to allow HCPs to provide results to patients during their visit was discussed by some as increasing their anxiety about the accuracy of the test:

‘I think it’s the emotional attachment to the result, and to the patient. Because I’m thinking, I want this to be the correct result for this patient who is sitting in front of me. Whereas if you’re giving them a result over the phone, or by text, it’s anonymous, it’s kind of colder. It’s detached.’ – Nurse3, (C1)

Respondents also focused on other practicalities of implementation. In post-implementation interviews, those that worked closely with the binx POCT were more likely to point out disadvantages. For example, while a nurse processing samples described the binx POCT as ‘noisy’, a clinician working in the same clinic that did not spend time in the room where it was placed described them as ‘completely fine’ and ‘pretty neat’. Further, although the binx POCT is described as a ‘a small, desktop instrument’ [16], a nurse implementing the device highlighted lack of space in the clinic for multiple instruments.

Discussion

To our knowledge, this is the first study among stakeholders in clinical care who have implemented a 30-minute STI POCT in practice. The factors that supported the decision to plan for adoption of the binx health *io* CT/NG Assay into participating sexual health services

included its usability within each local setting and the test being regarded by key decision-makers, such as clinical leads, as fit-for-purpose when compared with existing diagnostic technologies.

It has been argued that POCTs need to be affordable to enable their successful implementation [17]. The structure and funding of sexual health services within NHS England have undergone significant changes over the past decade, with services tendered to assure best value-for-budget [18,19], part of a global trend to reduce the cost of health services [20]. Our data indicate that within the process of decision-making, value of a new technology was considered within the broader economic and political context affecting the health service, such as a tendering process that values services' innovation. Potential political gains for modernising the service were described as nuancing decision-making processes for purchase. In addition, although upfront and ongoing costs of POCTs were considered potentially insurmountable barriers, these continued to be measured against potential patient and public health benefits by many respondents.

Our data indicate that, among our respondents, the need for solutions for specific aspects of individual service provision was greater than the desire for a one-size-fits-all POCT for STIs. While research has shown that UK patients attending sexual health services are likely to wait in clinic for POCT results in some circumstances [21], it has also been speculated that, in other contexts, when STI POCTs become widely implemented, the number of patients seeking testing may decrease due to apprehension over immediate results delivery [22]. We recommend further study of patients' opinions of routine STI POCTs, under multiple implementation conditions, to provide better understanding of best implementation pathways for STI POCTs.

In agreement with previous suggestions in the literature [23,24], attitudes of HCPs and managers towards innovation and technology are critical to the decision to purchase, and for successful implementation in practice. In our study, this was particularly salient if the views of lead clinicians and senior nursing staff were shared by junior HCPs. These findings are particularly valuable; it has been previously found that acceptability of POCTs among HCPs is crucial, yet there has been relatively little research done among HCPs regarding implementation [25,26].

Previous research suggests that accuracy of a new POCT is one of the most significant factors considered by key stakeholders in the adoption process [27-29]. It has been recognised that trust in new technologies is established not only through evidence of its published accuracy but also through comparison to similar technologies used in the past [30,31]. Sexual health services in the UK often deliver laboratory-based CT/NG results to patients via text message. With the introduction of a CT/NG POCT, HCPs are likely to provide patients with their results during their consultation. Our data show that the presence of the patient at the moment of delivering their diagnosis may increase HCPs' anxiety about the accuracy of POCT results. We recommend this be given special consideration during implementation plans.

Limitations

These interviews were conducted with staff from clinical services that expressed interest in taking part in a service evaluation of a CT/NG POCT. While the service decision to participate in the study does not imply the enthusiasm of all respondents, it is likely that those participating in the study were more likely than those who did not participate to have interest in novel technologies, POCTs in particular, and be interested in adopting them.

Consequently, there is a potential bias in our data for greater favourable opinions towards STI POCTs and other novel technologies than is generally present among this population.

Most respondents were HCPs (71% in ‘prior to implementation’ interviews and 78% in ‘after implementation’ follow-up interviews), and we only interviewed one commissioner. As a result, we were not able to consider a wide range of opinions of those responsible for commissioning NHS services and contributing to this higher-level decision-making, especially with regards to the economic and financial aspects associated with adoption of new technologies.

In addition, we were unable to observe the purchase of the POCT into routine clinical service due to delays in bringing the POCT to market. Subsequently, our post-implementation interviews were focused on discussion of implementation rather than purchase.

Conclusions

This article reports on the first-of-its-kind investigation of the implementation of a 30-minute molecular POCT for CT/NG into practice in sexual health services. This is a timely enquiry given the increase in commercial availability of rapid and POC tests for STIs, and the relative lack of data on social and contextual forces influencing new diagnostics’ adoption.

Our data report on key facilitators and barriers of POCT adoption from the perspective of HCPs, and show that nuances in decision-making around POCT adoption are likely to reflect local contexts, such as service tendering concerns and patient population needs. We also found HCP views of the POCTs are likely dependent on their role within the implementation process, underlining the need to include all levels of HCPs in clinical implementation plans.

We recommend further research to explore the interaction between patient acceptability and

implementation of new POCTs, to further understandings of how POCT use might improve clinical and public health outcomes in today's resource-constrained health services.

List of abbreviations

CT	<i>Chlamydia trachomatis</i>
EBM	Evidence-based medicine
FDA	Food and Drug Administration
HCP	Healthcare professional
POCT	Point-of-care test
NAAT	Nucleic acid amplification test
NG	<i>Neisseria gonorrhoeae</i>
NICE	National Institute for Clinical Excellence
STIs	Sexually Transmitted Infections

Availability of data and materials

The datasets generated and analysed during the current study are available in the Figshare repository, doi: 10.24376/rd.sgul.11830764

Competing interests

ADREU has received funding from binx health, Alere, Cepheid, SpeedDx, Mologic, Revolugen and Sekisui. SSF and EHE have been members of the BD Diagnostics Advisory

Panel on UK Provision of Sexual Health Services. This does not alter our adherence to BMJ Journals policies on sharing data and materials.

Funding

This project was funded by Innovate UK Small Business Research Initiative (SBRI) grant “Stratified medicine: connecting the UK infrastructure. Phase 2” to binx health. Ref: no. 90174-463338. This report is work commissioned by Innovate UK. The views expressed in this publication are those of the author(s) and not necessarily those of Innovate UK.

Authors' contributions

SSF and EHE conceived of the study. SSF initiated the study design and oversaw the study. AP and SSF implemented the study. AP wrote the initial draft of the manuscript. All authors contributed to and approved the final manuscript.

Acknowledgements

We are grateful to all participants. We also thank the members of our advisory committee: Lucy Parker, Kate Folkard, Cath Mercer, Sue Eaton, Merle Symonds, Gary Whitlock and Chris Price.

References

1. Adams EJ, Ehrlich A, Turner KME, Shah K, Macleod J, Goldenberg S, et al. Mapping patient pathways and estimating resource use for point of care versus standard testing

- and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. *BMJ Open*. 2014;4(7).
2. Huppert J, Hesse E, Gaydos CA. What is the point? How point-of-care sexually transmitted infection tests can impact infected patients. Vol. 9, *Point of Care*. 2010. p. 36–46.
3. Rompalo AM, Hsieh YH, Hogan T, Barnes M, Jett-Goheen M, Huppert JS, et al. Point-of-care tests for sexually transmissible infections: What do “end users” want? *Sex Health*. 2013;10(6):541–5.
4. Wiencek J, Nichols J. Issues in the practical implementation of POCT: Overcoming challenges. Vol. 16, *Expert Review of Molecular Diagnostics*. Taylor and Francis Ltd; 2016. p. 415–22.
5. Shaw JLV. Practical challenges related to point of care testing. Vol. 4, *Practical Laboratory Medicine*. Elsevier B.V.; 2016. p. 22–9.
6. Fitzgerald L, Ferlie E, Hawkins C. Innovation in healthcare: How does credible evidence influence professionals? *Heal Soc Care Community*. 2003;11(3):219–28.
7. Guyatt G, Cairns J, Churchill D, Cook D, Haynes B, Hirsh J, et al. Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine. *JAMA J Am Med Assoc*. 1992 Nov 4;268(17):2420–5.
8. Department of Health. A first class service: quality in the new NHS [Internet]. 1998 [cited 2020 Mar 2]. Available from: https://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4006902
9. Lambert H. Accounting for EBM: Notions of evidence in medicine. *Soc Sci Med*. 2006 Jun;62(11):2633–45.
10. Berg M. Problems and promises of the protocol. *Soc Sci Med*. 1997;44(8):1081–8.

- 480 11. Greenhalgh T. How to implement evidence-based healthcare. Wiley-Blackwell; 2018.
- 481 12. Fuller S, Clarke E, Harding-Esch E. 'There is no magic bullet.' Considerations for
482 adoption of molecular chlamydia and gonorrhoea point of care tests into routine care.
483 Sexually Transmitted Infections 2021;97:A120-A121.
- 484 13. Murtagh MM. The Point-of-Care Diagnostic Landscape for Sexually Transmitted
485 Infections (STIs). 2017;(May):1–63. Available from:
486 http://www.who.int/reproductivehealth/topics/rtis/Diagnostic_Landscape_2017.pdf%0
487 [Ahttps://www.who.int/reproductivehealth/topics/rtis/pocts/en/](https://www.who.int/reproductivehealth/topics/rtis/pocts/en/)
- 488 14. Fuller S, Furegato M, Phillips L, et al. First clinical evaluation of a 30-minute point-of-
489 care-test for Chlamydia trachomatis and Neisseria gonorrhoeae infection in UK sexual
490 health clinics. Sex Transm Infect 2021;97:A56.
- 491 15. Richie J, Lewis J, editors. Qualitative Research Practice. A guide for social science
492 students and researchers. SAGE Publications Ltd; 2003.
- 493 16. Van Der Pol B, Taylor SN, Mena L, Lebed J, McNeil CJ, Crane LS, et al. Evaluation
494 of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhea. JAMA
495 Netw open [Internet]. 2020. Available from: <https://jamanetwork.com/>
- 496 17. Peeling RW. Utilisation of rapid tests for sexually transmitted infections: Promises and
497 challenges. Open Infect Dis J. 2009;3(SPEC.ISS.1):156–68.
- 498 18. A Framework for Sexual Health Improvement in England [Internet]. [cited 2020 Mar
499 2]. Available from: [https://www.gov.uk/government/publications/a-framework-for-](https://www.gov.uk/government/publications/a-framework-for-sexual-health-improvement-in-england)
500 [sexual-health-improvement-in-england](https://www.gov.uk/government/publications/a-framework-for-sexual-health-improvement-in-england)
- 501 19. Carlin E. Tendering: Six steps to successful bidding. Sex Transm Infect. 2016 Aug
502 1;92(5):325–6.
- 503 20. Davies R, Lādavas E, Ron Davies, Parkova I, Vališevskis A, Briedis U, et al. 2019
504 Global health care outlook Shaping the future. Des Issues [Internet]. 2013;5(1):1–4.

Available from:

[https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-hc-outlook-](https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-hc-outlook-2019.pdf)

[2019.pdf](https://www.ncbi.nlm.nih.gov/books/NBK2665/)<http://www.ncbi.nlm.nih.gov/books/NBK2665/><http://dx.doi.org/10.1016/j.bios.2016.09.038><https://pdfs.semanticscholar.org/956b/6ee61>

21. Fuller SS, Pacho A, Broad CE, Nori A V., Harding-Esch EM, Sadiq ST. “It’s not a time spent issue, it’s a ‘what have you spent your time doing?’ issue. . .” A qualitative study of UK patient opinions and expectations for implementation of Point of Care Tests for sexually transmitted infections and antimicrobial resistance. PLoS One. 2019 Apr 1;14(4).
22. Natoli L, Guy RJ, Shephard M, Whiley D, Tabrizi SN, Ward J, et al. Public health implications of molecular point-of-care testing for chlamydia and gonorrhoea in remote primary care services in Australia: a qualitative study. BMJ Open. 2015 Apr 1;5(4):e006922.
23. Goldenberg MJ. On evidence and evidence-based medicine: Lessons from the philosophy of science. Soc Sci Med. 2006 Jun;62(11):2621–32.
24. Breckenridge-Sproat ST, Swiger PA, Belew DL, Raju D, Patrician PA, Loan LA. A program evaluation of the Patient CaringTouch System: A pre- and postimplementation assessment. Nurs Outlook. 2017 Sep 1;65(5):S109–19.
25. Natoli L, Guy RJ, Shephard M, Causer L, Badman SG, Hengel B, et al. “I do feel like a scientist at times”: A qualitative study of the acceptability of molecular point-of-care testing for chlamydia and gonorrhoea to primary care professionals in a remote high STI burden setting. PLoS One. 2015 Dec 1;10(12).
26. Engel N, Pant Pai N. Qualitative research on point-of-care testing strategies and programs for HIV. Vol. 15, Expert Review of Molecular Diagnostics. Expert Reviews

Ltd.; 2015. p. 71–5.

27. Gaydos C, Hardick J. Point of care diagnostics for sexually transmitted infections: Perspectives and advances. *Expert Rev Anti Infect Ther*. 2014;12(6):657–72.
28. Hsieh YH, Hogan MT, Barnes M, Jett-Goheen M, Huppert J, Rompalo AM, et al. Perceptions of an ideal point-of-care test for sexually transmitted infections - A qualitative study of focus group discussions with medical providers. *PLoS One*. 2010;5(11).
29. Hsieh YH, Gaydos CA, Hogan MT, Uy OM, Jackman J, Jett-Goheen M, et al. What qualities are most important to making a point of care test desirable for clinicians and others offering sexually transmitted infection testing? *PLoS One*. 2011;6(4).
30. Marks M, Esau T, Asugeni R, Harrington R, Diao J, Toloka H, et al. Point-of-care tests for syphilis and yaws in a low-income setting – A qualitative study of healthcare worker and patient experiences. *PLoS Negl Trop Dis*. 2018 Apr 19;12(4).
31. Land KJ, Boeras DI, Chen X-S, Ramsay AR, Peeling RW. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. *Nat Microbiol* [Internet]. 2019 Jan 13 [cited 2019 Aug 28];4(1):46–54. Available from: <http://www.nature.com/articles/s41564-018-0295-3>

Supporting information

S1 SRQR checklist